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Introduction
Large observational studies and clinical trials have shown that exces-
sive dietary sodium intake, mainly consumed as sodium chloride 
(salt), is an important trigger for hypertension and cardiovascular 
disease (CVD) [1–4]. Therefore, a low sodium diet is an important 
component of the preventative strategy for reducing the risk of CVD, 
especially in patients suffering from hypertension [5]. When it comes 
to ambition and reality there is a huge gap, which is not only ascrib-
able to the well-known lack of self-motivation for lifestyle changes 
in those patients but can be attributed to the extrinsic fact that salt 
is still used in great quantities as an important preserving agent and 
taste enhancer in Western food industry. As people especially in 
Western societies consume more and more processed foods it is not 
surprising that the latter account for about 80 % of daily salt intake 
and leaving only the remaining 20 % to the direct control of patients, 
which illustrates the limited nature of dietary approaches. This could 
be why daily salt consumption in Western societies remains with 
about 10 g per day much higher than recommended by the World 
Health Organization (WHO) [6–10].
As aberrance from physiological ranges of plasma sodium con-
centration causes relevant health problems like cerebral edema, 
plasma sodium concentration is strictly regulated. One of the main 
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AbStR ACt
First described in 1955 by Jerome W. Conn, primary aldoster-
onism (PA) today is well established as a relevant cause of sec-
ondary hypertension and accounts for about 5–10  % of hyper-
tensives. The importance of considering PA is based on its 
deleterious target organ damage far beyond the effect of ele-
vated blood pressure and on PA being a potentially curable 
form of hypertension. Aside the established contributory role 
of high dietary salt intake to arterial hypertension and cardio-
vascular disease, high salt intake is mandatory for aldoster-
one-mediated deleterious effects on target-organ damage in 
patients with primary aldosteronism. Consequently, counsel-
ling patients on the need to reduce salt intake represents a 
major component in the treatment of PA to minimize cardio-
vascular damage. Unfortunately, in PA patients salt intake is 
high and far beyond the target values of 5 g per day, recom-
mended by the World Health Organization. Insufficient patient 
motivation for lifestyle interventions can be further complicat-
ed by enhancing effects of aldosterone on salt appetite, via 
central and gustatory pathways. In this context, treatment for 
PA by adrenalectomy results in a spontaneous decrease in die-
tary salt intake and might therefore provide further reduction 
of cardiovascular risk in PA than specific medical treatment 
alone. Furthermore, there is evidence from clinical studies that 
even after sufficient treatment of PA dietary salt intake remains 
a relevant prognostic factor for cardiovascular risk. This review 
will focus on the synergistic benefits derived from both block-
ade of aldosterone-mediated effects and reduction in dietary 
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regulators is the steroid hormone aldosterone, which is synthesized 
in the zona glomerulosa of the adrenal cortex and acts predomi-
nately via the epithelial sodium channel (ENaC) in the distal 
nephron, as a physiologic regulator of water and salt homeostasis 
to maintain stable blood pressure. In case of primary aldosteronism 
(PA), the most frequent cause of endocrine hypertension, excess 
of aldosterone inappropriately high for salt status, results in target 
organ damage far beyond the effect of blood pressure changes 
[11–18]. Hence this review focuses on the current knowledge of 
the interaction of aldosterone and dietary salt intake as well as their 
impact on cardiovascular risk.
Dietary salt intake in PA: where are we now?
The negative effects of a high salt diet on hypertension and cardi-
ovascular risk in general are common consent [1–4]. Nevertheless, 
from time to time counterintuitive findings are published, these 
possibly influenced by methodological flaws especially in the way 
how dietary salt intake was estimated [19–21]. Based on the well-
known negative effects of high salt diet and a general awareness 
that Western style diets are unhealthy one should assume that PA 
patients, from a psychological point of view, consume salt in a 
(very) moderate manner. But what is moderate? In general condi-
tions ~1 g per day of dietary salt is supposed to be sufficient and 
5 g per day are recommended as upper limit by the WHO especial-
ly in patients with hypertension [6, 10, 22]. This is also based on 
data about our ancestors who consumed diets with an estimated 
salt content of ~1 g per day for hundreds of thousands of years. In-
terestingly it was no longer than about 5000–10 000 years ago, 
with the advent of farming that the addition of salt to food began 
[23, 24]. Unfortunately in this case, the low spontaneous mutation 
rate of DNA leaves us with the mismatch of a genetic background 
selected for survival under conditions of low salt intake and the very 
recent appearance of dietary salt abundance [24].
Consequently, patients with PA might be particularly vulnera-
ble in a high salt environment, given that aldosterone excess fur-
ther stimulates salt reabsorption and is also suspected to increase 
dietary salt intake. The latter finding could explain why several stud-
ies have shown that estimated dietary salt intake in PA patients is 
much higher than recommended [25–28]. For instance in a recent 
post-hoc analysis from the German Conn’s Registry we could show 
that PA patients have daily salt intake, estimated by 24-hour uri-
nary sodium excretion, amounting to 11.9 g in men and 9.4 g in 
women a consumption of salt which is at least as high as the Ger-
man median of 10.0 g in men and 8.4 g in women and doubles the 
target values initiated by the WHO [6, 29, 30].
Does aldosterone impact dietary salt intake?
It is well known that aldosterone is one of the key regulators of salt 
and water homeostasis. Hereby salt loss is a strong stimulus for the 
release of aldosterone from the adrenal glands, although plasma 
sodium levels are usually within the physiological ranges [31]. Be-
side its salt retaining effect in the distal nephron of the kidney, 
where it leads to sodium reabsorption, aldosterone has also been 
shown to modulate salt appetite. Two major mechanisms are dis-
cussed: the impact of aldosterone on sodium sensing via ENaC in 
the tongue and direct aldosterone action on the brain as there the 
mineralocorticoid receptor (MR) is widely expressed.
We know from rodent studies that adrenalectomy causes renal 
salt loss and that administration of mineralocorticoids such as de-
oxycorticosterone (DOC), a precursor of aldosterone, or aldoster-
one at high doses increases salt intake in adrenalectomized as well 
as adrenal-intact rats, with the latter showing higher salt intake at 
comparable doses of DOC [32–36]. Furthermore, it could be shown 
that administration of aldosterone either to the forebrain or to the 
hindbrain increased sodium intake in rodents. This effect could be 
blocked by pretreatment with intracerebroventricular administra-
tion of MRA or antisense oligodeoxynucleotides against the MR but 
not against the glucocorticoid receptor (GR) [32, 37–39]. Francis 
et al. showed a faster reduction of salt intake following cerebroven-
tricular versus intraperitoneal administration of spironolactone 
[40]. Changes in sodium intake were reported to occur rapidly 
(after 15 min) following DOCA administration into the amygdala 
which is in accordance with data from humans [38, 41]. This strong-
ly argues for central aldosterone effects presumably via the MR in 
the regulation of salt appetite [42].
One of the most intensively studied areas in the brain is the hip-
pocampus. Here the MR and the GR are widely expressed [43]. How-
ever due to the lack of 11β-hydroxysteroid dehydrogenase type 2 
(11β-HSD2), which inactivates cortisol to cortisone, the selectivity 
of the MR is quite low for aldosterone regarding the 100-fold higher 
concentration of cortisol [44]. Both steroids, however, show equiv-
alent affinity to the MR, indicating that in tissues like the hippocam-
pus the overwhelming majority of MR is occupied by glucocorticoids. 
Therefore, under physiological conditions the hippocampus seems 
to have only little effect on the aldosterone-mediated modulation 
of salt appetite, and this may be dose dependent. To our knowledge, 
there are only a couple of areas in the brain in which the MR and 11β-
HSD2 are co-expressed resulting in a high selectivity for aldosterone 
action on the MR. These are mainly the nucleus of the solitary tract 
(NTS), which could be shown to play an important role for salt intake 
under aldosterone stimulation [37, 43, 45–47]. In this context 
brain-specific knockout of 11β-HSD2 was shown to increase sodium 
intake in mice, which suggests that under these conditions salt ap-
petite may also be regulated by glucocorticoids [48]. Apart of that 
baroreceptors and other neural and endocrine signals are considered 
to modulate aldosterone-induced salt appetite but in total the exact 
mechanisms are still not fully understood and there is a lively debate 
on the role of aldosterone and the MR in the brain with also contro-
versial findings [45, 49–52].
Besides the kidney, ENaC is also expressed in the gustatory sys-
tem, namely in the taste buds of the tongue. Knockout of ENaC-al-
pha in taste-receptor cells resulted in almost complete loss of salt 
attraction in contrast to water in mice [53]. On the other hand, 
DOC-treated rats showed an increase in saline preference and even 
a loss of aversion against hypertonic sodium concentrations [32]. 
In line with these findings Sakamoto et al. reported a decrease in 
amiloride-sensitive salt taste nerve responses in aldosterone/sodi-
um chloride treated rats, which could be a mediator for the better 
palatability for hypertonic sodium chloride solutions in rodents fa-
voring higher salt intake under these circumstances (▶Fig. 1) [54].
We have studied the effects of aldosterone on gustatory sodi-
um detection in humans using sodium chloride serial dilution in 
patients with PA and essential hypertension. For this purpose, 10 
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0.5 mmol/l to 256 mmol/l were used. Patients received a cup with 
either sample solution or distilled water. They were asked to keep 
the solution in their mouth for a few seconds and then to report on 
taste sensation. Preliminary results show that the recognition 
threshold, the concentration which was identified twice as salty 
tasting by the patients, is significantly higher in patients suffering 
from PA [55]. This is in accordance with the aforementioned ani-
mal studies and indicates the impact of aldosterone on salt tasting 
in patients with PA.
Synergistic effects of aldosterone excess and high 
salt diet
In the last decades, evidence has been gathered that deleterious 
cardiovascular and cerebrovascular effects in PA are (only) caused 
by aldosterone levels inappropriate for salt status [18, 56, 57]. Al-
ready in the 1990s, Brilla and colleagues showed that aldosterone 
administration causes myocardial fibrosis on a high sodium diet 
[16]. Similar results were reported by Young et al. who extended 
these analyses, whereas Rocha et al. could show that these effects 
could be blocked by administration of mineralocorticoid receptor 
antagonists (MRA) or adrenalectomy (ADX) [15, 17, 18]. Interest-
ingly neither blood pressure increases, nor cardiovascular changes 
were caused by sodium deprivation even in the state of high aldos-
terone levels [16]. In accordance with these findings Funder report-
ed New Guinea hill tribes with extraordinary low sodium intake of 
2–3 mEq/day (~46–69 mg/day) who, despite very high aldoster-
one levels, showed normal blood pressure and no cardiovascular 
or renal damage [58].
The effect of high salt diet and inappropriate aldosterone levels 
on cardiovascular risk in PA was initially thought only to be related 
to blood pressure increase through fluid retention. However, ani-
mal studies have shown that blood pressure increases through ad-
ministration of aldosterone are not necessarily caused by an in-
crease in circulating volume [58, 59]. In another model for PA ad-
ministration of eplerenone reduced cerebral and renal vascular 
damage without relevant effects on blood pressure levels [18]. In 
addition, Stowasser et al. have shown a significantly greater extent 
of cardiovascular damage in normotensive patients suffering from 
familial hyperaldosteronism type 1 compared with matched con-
trols [60]. In this context there is substantial evidence for blood 
pressure-independent aldosterone-mediated tissue damage as also 
reported by Monticone and colleagues in a recent meta-analysis 
[12].
High dietary salt intake itself is associated with arterial hyper-
tension as well as epithelial swelling, vascular stiffening, increased 
pulse pressure, left ventricular hypertrophy and albuminuria 
[61–63]. With the majority of these effects being blood pressure- 
related, evidence also suggests direct negative impact of dietary 
sodium. It has been shown that high salt diet increases angioten-
sin II type 1 (AT1) and decreases angiotensin II type 2 (AT2) recep-
tors, thereby promoting vasoconstriction and cardiovascular dam-
age [64, 65]. Counterintuitive to pathophysiological considerations 
increased activity of cardiac aldosterone synthase (CYP11B2) and 
finally higher cardiac aldosterone synthesis were reported under 
salt administration, findings which are controversially discussed 
[66–68]. However, this could further add insult to cardiac injury 
▶Fig. 1 Simplified model for the supposed effects of aldosterone on the regulation of salt intake: Aldosterone has several effector organs to regu-
late sodium homeostasis. In the brain it is supposed to operate via similar molecular mechanisms as established for the periphery, including activa-
tion of MR, to ultimately impact on sodium appetite. Aldosterone presumably also affects sodium sensing in the tongue, most likely via ENaC. In 
conjunction with the inhibition of sodium aversion in the brain and additive effects of angiotensin II these mechanisms allow for an increase in salt 
intake. Apart from that, higher plasma sodium concentration and respectively sodium concentration in the cerebral spinal fluid inhibits sodium 
appetite. To minimize salt loss aldosterone increases renal and intestinal salt (re)absorption. Ang II: Angiotensin II; Na + CSF: sodium sensor for the 
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under these circumstances. Another incompletely solved issue rep-
resents endogenous ouabain (EO) or ouabain-like compounds. 
These compounds were reported to be released in response to 
ACTH, angiotensin II and sodium administration and to be linked 
to aldosterone levels [58, 69, 70]. On the one hand, the secretion 
of EO is supposed to cause vasoconstriction and hypertension and 
thus could explain synergistic effects of aldosterone and high die-
tary salt intake. On the other hand, to date it is not even sure, if EO 
actually exists or not, as some research groups have been unable 
to detect EO in human circulation [58, 71, 72].
One alternative mechanism to explain the interaction of salt and 
aldosterone might be a high salt intake-mediated overexpression 
of transforming growth factor β1 which is known to exert profibrot-
ic actions [73].
Moreover, effects of salt intake on redox state are frequently report-
ed. In general, oxidative stress is characterized by an imbalance between 
the generation of reactive oxygen species (ROS), oxygen-containing 
molecules with an unpaired electron, especially the superoxide anion 
O2–, and their detoxification by antioxidant systems such as superoxide 
dismutase and catalase. ROS are generated by normal respiration of cells 
and amongst others by xanthine oxidase and NADPH oxidase. 8-Isopros-
tane is one of the stable products generated under the impact of ROS 
and it is hence used as a marker of oxidative stress in vivo [74, 75]. In this 
context it has been shown that in salt-sensitive hypertension, high salt 
intake results in higher plasma concentrations of the lipid peroxidation 
product isoprostanes [76, 77]. In rats on a high salt diet it could further 
be shown that the renal expression of NAD(P)H oxidase is increased re-
sulting in further oxidative stress [78].
Another link between oxidative stress and high dietary salt in-
take are the pro-inflammatory effects mediated by changes in gut 
microbiota [79, 80]. Animal as well as human studies could show 
gut dysbiosis in subjects suffering from hypertension [81, 82]. This 
is supposed to impact negatively on the intestinal mucosa and in-
crease its permeability for pathogens, eventually promoting in-
flammation and oxidative stress [83, 84]. The relevance of the gut 
microbial composition was underlined by data from fecal microbi-
ota transplant (FMT) studies where FMT from hypertensive rats to 
normotensive rats elevated blood pressure in the latter [85]. Toral 
and colleagues identified the pro-inflammatory interleukin 17, pro-
duced by T helper 17 (TH 17) cells, to be essential for the FMT-in-
duced blood pressure increase as well as the effects on endothelial 
dysfunction [85]. In this context, administration of a neutralizing 
antibody against IL-17 reduced blood pressure and improved en-
dothelial dysfunction induced by FMT [85].
High dietary salt intake by itself has been shown to increase plas-
ma levels of the pro-inflammatory cytokines IL-6 and IL-23 and to 
activate TH 17 cells, resulting in inflammatory oxidative stress, re-
spectively [79, 86]. Further it has been linked to gut dysbiosis fa-
voring colonization by Prevotella and other species which are asso-
ciated with elevated blood pressure and auto inflammatory diseas-
es as well as the depletion of Lactobacillus spp. [79, 87–91]. In line 
with these findings Wilck and colleagues could show that adminis-
tration of Lactobacillus murinus protected mice from activation of 
TH 17 cells and abrogated hypertension when challenged with a 
high salt diet [79]. Comparable with the results of the animal stud-
ies they could also show a reduction of Lactobacillus spp. as well as 
an increase in TH 17 cells and blood pressure in humans on a high-
salt diet. Taking these findings into account the impact of salt in-
take on gut microbiota and consecutively TH 17 mediated inflam-
mation could be another mechanism of salt induced oxidative 
stress. Interestingly, aldosterone has also been reported to pro-
mote the TH 17 pathway while spironolactone potentially blocks 
the activation of TH 17 cells [92, 93].
Altogether there is accumulating evidence for high salt intake 
raising oxidative stress in animals as well as in humans. Under con-
ditions of oxidative stress, the aldosterone-independent activation 
of the MR has received particular interest.
To better understand the consequences of an altered redox state 
it is important to recall that the classical effects of aldosterone are 
MR-dependent genomic effects on sodium excretion in the distal 
nephron of the kidney. In general, the MR has similar affinity for al-
dosterone and cortisol. As aldosterone accounts only for about 1 % 
of free steroids in epithelial tissues (e. g., kidney, colon, sweat and 
salivary gland) it is the enzyme 11β-HSD2, which converts cortisol 
into its inactive metabolite cortisone, with parallel conversion of 
the cofactor NAD +  to NADH, thereby rendering aldosterone to the 
main activator of epithelial MR [44, 94, 95]. In other tissues, such 
as the heart, 11β-HSD2 is not expressed at relevant levels, leading 
to cortisol as the primary ligand. Of note, cortisol under normal 
redox conditions is supposed to act as an MR antagonist [96, 97].
In the case of oxidative stress, Mihailidou and colleagues 
showed, using experimentally induced myocardial infarction in ro-
dents as a trigger, that exogenous administration of cortisol as well 
as physiological levels of glucocorticoids both increase the infarct 
area. As this effect could not be blocked by the glucocorticoid/pro-
gesterone antagonist RU486 but only by spironolactone it seems 
that glucocorticoids can act as MR agonists in case of oxidative 
stress and hence increase cardiovascular damage [97]. The rele-
vance of oxidative stress for these agonistic effects was further 
strengthened by Mihailidou as the administration of TEMPOL (4-hy-
droxy-2,2,6,6-tetramethylpiperidine-N-oxyl), a superoxide dismu-
tase mimetic, also blocked the pro-apoptotic effects of aldoster-
one and cortisol [97]. These findings might provide a treatment ra-
tionale for patients suffering from PA: not only as aldosterone and 
salt excess increase oxidative stress by themselves but in addition 
because those patients frequently feature cortisol co-secretion 
[98, 99]. The latter aggravates cardiovascular damage in scenarios 
with both high and low oxidative stress as glucocorticoid excess im-
pairs the conversion of cortisol to cortisone, leading to glucocorti-
coid-mediated mineralocorticoid effects even in 11β-HSD2 pro-
tected epithelial tissues (▶Table 1) [100–105]. As stated previous-
ly, changes in redox state may further aggravate glucocorticoid MR 
agonism. This is attributed to a loss of NADH which is supposed to 
act as a putative ligand specific co-repressor exclusively at gluco-
corticoid-occupied MR [96, 106–108].
Relevance of dietary salt intake for patients with PA 
following initiation of treatment
Besides the synergistic effects of salt and aldosterone excess, there 
is accumulating evidence from clinical studies that high salt intake 
plays an important role for cardiovascular risk even after success-
ful treatment of PA. In a recent study it has been shown that lower 
dietary sodium intake, estimated by measuring 24-hour urinary so-
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decrease of left ventricular mass index (LVMI) [25]. This effect was 
independent of blood pressure and treatment modality. Pimenta 
and colleagues observed that proteinuria was significantly reduced 
after unilateral adrenalectomy for the treatment of PA while the 
positive correlations of proteinuria and salt intake persisted even 
after the procedure [26]. Since both LVMI and proteinuria are inde-
pendent cardiovascular risk factors, a low sodium diet could im-
prove target-organ protection even after successful treatment of 
PA.
Interestingly, in a post hoc analysis of 148 consecutive PA pa-
tients of the German Conn’s Registry (66 with unilateral and 82 
with bilateral PA) there was a significant reduction of dietary salt 
intake, as estimated by 24-hour urinary sodium excretion, after one 
as well as three-years of follow-up, in patients who had undergone 
unilateral adrenalectomy but not in those on MRA treatment [29]. 
However, this finding contrasts with data from Catena and col-
leagues who detected a decrease in salt intake in both treatment 
groups at one-year of follow-up. This discrepancy could be attrib-
utable to different treatment strategies in both cohorts with vary-
ing dosing of MRA and consecutively MR antagonism as well as the 
intensity of lifestyle intervention [29]. A decrease in salt intake after 
ADX constitutes an independent protective element favoring car-
diovascular risk reduction in patients with unilateral PA who opt for 
surgery.
In this context, it is of interest that Hundemer and colleagues 
showed a strong correlation between plasma renin activity and car-
diovascular outcome in PA patients undergoing MRA treatment 
[109]. In this study, 134 patients with suppressed plasma renin ac-
tivity had a risk profile almost three times higher than patients with 
unsuppressed renin although the two groups did not differ in blood 
pressure levels. The authors attributed this increased risk to insuf-
ficient MRA treatment. As sodium intake was not recorded it can 
be speculated if it was not at least in part dietary sodium restriction 
which was associated with higher renin levels and could therefore 
act as a confounder for a more favorable cardiovascular outcome 
[110].
Conclusions
Huge evidence from experimental and clinical studies indicates that 
aldosterone excess inadequate for salt status is required to cause 
cardiovascular and cerebrovascular target organ damage in pa-
tients with PA. Here it should be kept in mind that the central ef-
fects of aldosterone increase salt appetite and thereby potentially 
counteract lifestyle interventions aimed at the reduction of dietary 
salt intake. Clinicians should, in addition to providing sufficient 
treatment of aldosterone excess in PA, not hesitate to encourage 
these patients to reduce their daily salt intake in order to minimize 
target organ damage, especially as usually after a few weeks of salt 
reduction the gustatory perception of salt is increased in general 
public which might help maintaining a lower dietary salt intake 
[111].
Further studies are required to collect more data about the ef-
fectiveness of strategies to reduce long-term dietary salt intake in 
PA and the impact of decreases in salt intake on cardiovascular risk, 
particularly after initiation of treatment for PA.
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